Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling
Jiying Liu,Guangyao Fang,Cong Lan,Chenming Qiu,Li Yao,Qian Zhang,Jingtang Hu,Yaolei Zhang,Yongjian Yang,Yan Zhang
DOI: https://doi.org/10.2147/dddt.s444605
IF: 4.3188
2024-03-12
Drug Design Development and Therapy
Abstract:Jiying Liu, 1– 3 Guangyao Fang, 2, 4 Cong Lan, 2 Chenming Qiu, 5 Li Yao, 2 Qian Zhang, 2 Jingtang Hu, 2 Yaolei Zhang, 6 Yongjian Yang, 1, 2 Yan Zhang 1, 2 1 Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 2 Department of Cardiology, General Hospital of Western Theater Command, Chengdu, Sichuan, 610083, People's Republic of China; 3 Department of Cardiology, The Third People's Hospital of Yibin, Yibin, Sichuan, 644000, People's Republic of China; 4 College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, 610083, People's Republic of China; 5 Department of Burn and Plastic Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan, 610083, People's Republic of China; 6 Basic Medical Laboratory, General Hospital of Western Theater Command, Chengdu, Sichuan, 610083, People's Republic of China Correspondence: Yongjian Yang, Department of Cardiology, General Hospital of Western Theater Command, Chengdu, Sichuan, 610083, People's Republic of China, Tel +86-13880827421, Email Yan Zhang, Department of Cardiology, General Hospital of Western Theater Command, Chengdu, Sichuan, 610083, People's Republic of China, Tel +86-18980530960, Email Purpose: Pulmonary arterial hypertension (PAH) is a devastating disease with little effective treatment. The proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by the nuclear factor-κB (NF-κB) signaling activation plays a pivotal role in the pathogenesis of PAH. Forsythoside B (FTS•B) possesses inhibitory effect on NF-κB signaling pathway. The present study aims to explore the effects and mechanisms of FTS•B in PAH. Methods: Sprague–Dawley rats received monocrotaline (MCT) intraperitoneal injection to establish PAH model, and FTS•B was co-treated after MCT injection. Right ventricular hypertrophy and pulmonary artery pressure were measured by echocardiography and right heart catheterization, respectively. Histological alterations were detected by H&E staining and immunohistochemistry. FTS•B's role in PASMC proliferation and migration were evaluated by CCK-8 and wound healing assay. To investigate the underlying mechanisms, Western blotting, immunofluorescence staining and ELISA were conducted. The NF-κB activator PMA was used to investigate the role of NF-κB in FTS•B's protective effects against PAH. Results: FTS•B markedly alleviated MCT-induced vascular remodeling and pulmonary artery pressure, and improved right ventricular hypertrophy and survival. FTS•B also reversed PDGF-BB-induced PASMC proliferation and migration, decreased PCNA and CyclinD1 expression in vitro. The elevated levels of IL-1β and IL-6 caused by MCT were decreased by FTS•B. Mechanistically, MCT-triggered phosphorylation of p65, IκBα, IKKα and IKKβ was blunted by FTS•B. FTS•B also reversed MCT-induced nuclear translocation of p65. However, all these protective effects were blocked by PMA-mediated NF-κB activation. Conclusion: FTS•B effectively attenuates PAH by suppressing the NF-κB signaling pathway to attenuate vascular remodeling. FTS•B might be a promising drug candidate with clinical translational potential for the treatment of PAH. Keywords: Forsythoside B, pulmonary arterial hypertension, NF-κB signaling pathway, pulmonary vascular remodeling, pulmonary artery smooth muscle cell Pulmonary arterial hypertension (PAH) is defined hemodynamically by a mean pulmonary arterial pressure greater than 20 mmHg, a pulmonary artery wedge pressure lower than 15 mmHg, and a pulmonary vascular resistance of at least 3 wood units. 1 PAH is known as a cardiovascular malignancy, and remains a key cause of death worldwide. 2 Elevated pulmonary artery pressure in PAH leads to increased afterload of the right heart, resulting in decompensated hypertrophy of the right heart, ventricular dilation, and eventually right heart failure and fatality. 3 Furthermore, in addition to posing a risk on its own, PAH can also complicate the identification and management of common illnesses such as chronic obstructive pulmonary disease and interstitial lung diseases, consequently exacerbating the progression of these conditions and increasing mortality rates. 4 Currently, the treatment for PAH focuses on addressing the dysfunction of the endothelium by blocking the endothelin pathway and improving the pathways of prostacyclin (PGI2) and nitric oxide (NO). 5 Despite significant advancements in the treatment strategy, achieving a full cure for PAH remains unattainable. The 3-year surviva -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal